1. Treatment of
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (
HER2)–negative
breast cancer patients who have a mutated phosphatidylinositol 3-kinase (PIK3) with the PIK3 inhibitor alpelisib, in addition to fulvestrant, increased progression free survival compared to treatment with fulvestrant alone. 2. The most common severe adverse effects in alpelisib-fulvestrant treated patients were hyperglycemia […]